2025年长三角药品监管工作会议在南京召开

Core Insights - The 2025 Yangtze River Delta Pharmaceutical Regulatory Work Conference was held in Nanjing, focusing on enhancing regulatory capabilities and fostering a new pattern of regional pharmaceutical industry development [1][3] - The conference resulted in the signing of several cooperation agreements aimed at integrating pharmaceutical regulatory efforts across the Yangtze River Delta region [3][5] Group 1: Regulatory Collaboration - The regulatory authorities from Jiangsu, Zhejiang, Anhui, and Shanghai engaged in discussions on integrated regulatory collaboration, signing memorandums for clinical trial institution regulation and sharing provincial standards for traditional Chinese medicine [3] - A framework agreement for collaborative regulation of online pharmaceutical sales and third-party platforms was established, along with the launch of a collaborative platform for inspecting commissioned production enterprises and handling non-compliant products [3] Group 2: Strategic Goals and Achievements - The Yangtze River Delta integration is a significant national strategy initiated by President Xi Jinping, with the seventh year of its elevation to a national strategy [5] - The region contributes 30% of the national biopharmaceutical output, 30% of drug sales, and 70% of domestically produced Class I new drugs, with biopharmaceutical output exceeding 1 trillion [5] Group 3: Future Directions - The regulatory bodies aim to enhance regional integration and collaboration, focusing on mechanisms for mutual recognition, joint inspections, and shared resources to create a closed-loop regulatory system [5] - Emphasis will be placed on innovation and service collaboration to strengthen the pharmaceutical industry and ensure the safety and effectiveness of medications for the public [5]